China Grand Pharmaceutical and Healthcare Holdings Limited announced executive changes. The company announced that Mr. Liu Chengwei and Mr. Hu Bo, after serving as executive Directors for 12 years since 2008, have retired as executive Directors at the conclusion of the AGM due to their own decisions to devote more time to their personal engagements, and they have ceased to be chairman and deputy chairman of the Board respectively. The company further announced further announced that at the AGM, Dr. Tang Wei Kun and Dr. Shi Lin have been appointed as executive Directors with effect from the conclusion of the AGM. Dr. Tang is also appointed as the chairman of the Board and a member of the remuneration committee of the Company. Dr. Tang Weikun joined Grand Pharma (China) Co. Ltd. in 2012 and worked for several companies of the Group. He has been the assistant of the president of Grand Pharma (China) since April 2019, and was appointed as the president of Grand Pharma (China) with effect from June 1, 2021. Dr. Tang has overall responsible for the operation of Grand Pharma (China). Dr. Tang completed his life science and technology undergraduate education at Wuhan University in 2007, and obtained his doctoral degree in microbiology from the College of Life Sciences, Wuhan University in 2012. Dr. Shi Lin joined the Group in 2019 and is currently the deputy president and chief pharmaceutical officer of Grand Pharma (China). Before joining the Group, she had been the EU Regulatory Leader in Global Regulatory Affairs (GRA) Neuroscience of Janssen R&D in Belgium. Dr. Shi has over 20 years of clinical and research experience in the pharmaceutical industry, with significant experience working with global multifunctional matrix teams to drive forward complex projects. She led various applications for clinical trials in different countries in Europe and the United States, particularly in relation to strategic assessments in first clinical trials and innovative research paths. Dr. Shi obtained her doctoral degree in medical sciences from Vrije Universiteit Brussel in 2005. She has been appointed as professor and visiting fellow in various universities, an expert engaged under the Help Motherland through Elite Intellectual Resources from Overseas Programme established by the China Association for Science and Technology, visiting professor of Tongji Medical College affiliated to Huazhong University of Science and Technology in Wuhan and the Third Affiliated Hospital of the Third Military Medical University in Chongqing.